On Saturday, Donald Trump signed an executive order aimed at accelerating clinical research into psychedelic drugs. The order focuses on expanding federal funding, reducing bureaucratic barriers, and speeding up regulatory timelines. The move signals a notable shift in U.S. federal posture toward psychedelics—distinct from ongoing developments at the state level—and arguably represents one of the most significant federal actions on psychedelic research and access to date.

A new meta-analysis challenges the narrative that psychedelic therapy outperforms antidepressants, showing comparable effectiveness when trials are evaluated under similar conditions.

In January 2025, the then Minister for Policing, Fire and Crime Prevention commissioned the Advisory Council on the Misuse of Drugs (ACMD) to provide an updated assessment of ketamine-related harms, consider its appropriate legal classification, and advise on how best to reduce harms associated with ketamine use.